Skip to main content

ACI's 15th Advanced Forum on Fraud & Abuse in the Sales and Marketing of Drugs

American Conference Institute

Mar
13
2015

Date: March 13, 2015

Time: 10:30AM

Location: Omni Parker House, Boston, MA

Topics

  • The Federal Anti-Kickback Statute: Identifying Enforcement Priorities Including Educational Activities, Coupons, and More
     

In this time of increasing regulation and transparency, attend the one event that will prepare you to reduce the risk of claims under the FCA, Anti-Kickback, Anti-Bribery, and FCPA, as well as criminal prosecutions, fines and negative publicity. This annual conference will enable you to reshape your compliance programs to reflect recent government guidance, changes in enforcement priorities and to develop corporate policies that guard against future claims, violations and government oversight.

For the first time this iteration of the iconic and industry leading conference: Fraud and Abuse in the Sales and Marketing of Drugs is being held in the jurisdiction with strongest arm of enforcement in the nation, Massachusetts. As such, not only will we have an unparalleled faculty of U.S. Attorneys, including two from Boston, but we will also be featuring United States Attorney Carmen Ortiz, who will deliver a keynote address to open this event with insight into what the DOJ’s enforcement priorities are.

Larry Freedman will be moderating the panel, "The Federal Anti-Kickback Statute: Identifying Enforcement Priorities Including Educational Activities, Coupons, and More." Topics include:

  • Educational activities for clinicians and other HCPs: what circumstances will trigger government enforcement?
  • Best practices to making medication more affordable to customers while avoiding the potential landmines of Anti-Kickback violations
  • Navigating the diversity of District Court decisions

 

Speakers

Laurence J. Freedman is a Mintz attorney who represents health care and life sciences clients. Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations.